{
    "id": 16232,
    "fullName": "NONO - TFE3",
    "impact": "fusion",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "NONO-TFE3 results from the fusion of NONO and TFE3, which results in aberrant localization relative to either Nono and Tfe3 and reduced Tfe3 transcriptional activity (PMID: 11313942), and therefore is predicted to lead to a loss of protein function. NONO-TFE3 has been identified in renal cell carcinoma (PMID: 11313942, PMID: 27934879).",
            "references": [
                {
                    "id": 16510,
                    "pubMedId": 27934879,
                    "title": "Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27934879"
                },
                {
                    "id": 4208,
                    "pubMedId": 11313942,
                    "title": "PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11313942"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4841,
        "geneSymbol": "NONO",
        "terms": [
            "NONO",
            "MRXS34",
            "NMT55",
            "NRB54",
            "P54",
            "P54NRB",
            "PPP1R114"
        ]
    },
    "variant": "NONO - TFE3",
    "createDate": "01/06/2016",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 7030,
                "geneSymbol": "TFE3",
                "terms": [
                    "TFE3",
                    "bHLHe33",
                    "RCCP2",
                    "RCCX1",
                    "TFEA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15802,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited proliferation of a renal cell carcinoma cell line harboring NONO-TFE3 in culture, and demonstrated increased anti-proliferative effect compared to PI3K or mTOR inhibition alone (PMID: 30061365).",
            "molecularProfile": {
                "id": 16504,
                "profileName": "NONO - TFE3"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13814,
                    "pubMedId": 30061365,
                    "title": "Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30061365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16504,
            "profileName": "NONO - TFE3",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}